| A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma (NCT00111007) | Bayer | 2005-05-01 |
| Characterization of Brain Metastases (NCT00184275) | Norwegian University of Science and Technology | 2005-05-01 |
| Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma (NCT00109005) | National Cancer Institute (NCI) | 2005-04-01 |
| A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma (NCT00492297) | Bayer | 2005-04-01 |
| Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma (NCT00110994) | Bayer | 2005-04-01 |
| Targeted Intervention for Melanoma Prevention (NCT00394134) | M.D. Anderson Cancer Center | 2005-04-01 |
| Use of 852A in Metastatic Cutaneous Melanoma. (NCT00189332) | Pfizer | 2005-02-01 |
| Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer (NCT01215500) | University of Chicago | 2005-01-01 |
| Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2 (NCT00844064) | Isarna Therapeutics GmbH | 2005-01-01 |
| Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma (NCT00258687) | Dana-Farber Cancer Institute | 2005-01-01 |
| Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma (NCT00591370) | Memorial Sloan Kettering Cancer Center | 2005-01-01 |
| Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma (NCT00094107) | Pfizer | 2004-12-01 |
| Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma (NCT00185302) | Bayer | 2004-12-01 |
| Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy (NCT00099970) | PDL BioPharma, Inc. | 2004-12-01 |
| Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma (NCT00107718) | GlaxoSmithKline | 2004-11-15 |
| Proton MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response. (NCT00184288) | Norwegian University of Science and Technology | 2004-11-01 |
| Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema (NCT00441662) | Wills Eye | 2004-11-01 |
| Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) (NCT00091572) | Merck Sharp & Dohme LLC | 2004-10-20 |
| Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells (NCT00515983) | José Mordoh, M.D., Ph.D. | 2004-10-01 |
| Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB (NCT00204529) | University Hospital Tuebingen | 2004-10-01 |
| Multicenter Selective Lymphadenectomy Trial II (MSLT-II) (NCT00297895) | Saint John's Cancer Institute | 2004-09-30 |
| Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions (NCT00091689) | Pfizer | 2004-09-01 |
| MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma (NCT00094653) | Bristol-Myers Squibb | 2004-09-01 |
| Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma (NCT00466687) | Vanderbilt-Ingram Cancer Center | 2004-09-01 |
| Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients (NCT00559026) | Istituto Superiore di Sanità | 2004-09-01 |
| An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation (NCT00132704) | Memorial Sloan Kettering Cancer Center | 2004-08-01 |
| Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients (NCT00160992) | University of Lausanne Hospitals | 2004-07-01 |
| Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases (NCT00587964) | Memorial Sloan Kettering Cancer Center | 2004-06-01 |
| Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38 (NCT00912574) | University of Virginia | 2004-06-01 |
| STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma (NCT00084214) | Synta Pharmaceuticals Corp. | 2004-05-01 |
| Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma (NCT00184067) | University of Southern California | 2004-05-01 |
| Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer (NCT00095108) | ZymoGenetics | 2004-05-01 |
| Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients (NCT00847106) | Radboud University Medical Center | 2004-03-01 |
| Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma (NCT00080353) | National Cancer Institute (NCI) | 2004-03-01 |
| MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma. (NCT00147550) | Pfizer | 2004-02-01 |
| Immunotherapy of Stage III/IV Melanoma Patients (NCT00112242) | Centre Hospitalier Universitaire Vaudois | 2004-02-01 |
| Eligibility Screening for the NIH Intramural Research Program Clinical Protocols (NCT00026754) | National Cancer Institute (NCI) | 2004-01-14 |
| Clinical and Histological Features of Head and Neck Melanoma (NCT02883933) | CHU de Reims | 2004-01-01 |
| Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity (NCT00580060) | Memorial Sloan Kettering Cancer Center | 2003-12-01 |
| Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma (NCT00518206) | Ludwig Institute for Cancer Research | 2003-11-28 |
| Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF) (NCT00809588) | Dana-Farber Cancer Institute | 2003-10-16 |
| Harvesting Cells for Experimental Cancer Treatments (NCT00068003) | National Cancer Institute (NCI) | 2003-09-08 |
| Multicentric Cohort of Melanoma Patients in Ile de France Area (NCT00839410) | Assistance Publique - Hôpitaux de Paris | 2003-09-01 |
| Health Communication in Families (NCT00597961) | Memorial Sloan Kettering Cancer Center | 2003-08-12 |
| Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma (NCT00066196) | MedImmune LLC | 2003-08-01 |
| Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma (NCT00068211) | Genzyme, a Sanofi Company | 2003-08-01 |
| Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases (NCT00204581) | University Hospital Tuebingen | 2003-08-01 |
| A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma (NCT00062933) | National Cancer Institute (NCI) | 2003-06-01 |
| Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma (NCT00512798) | Vanderbilt-Ingram Cancer Center | 2003-06-01 |
| PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial) (NCT00221702) | University Hospital, Bordeaux | 2003-06-01 |
| Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum (NCT00046189) | National Cancer Institute (NCI) | 2003-04-07 |
| Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients (NCT00112229) | Centre Hospitalier Universitaire Vaudois | 2003-04-01 |
| Peptide Vaccination for Patients at High Risk for Recurrent Melanoma (NCT00059475) | National Cancer Institute (NCI) | 2003-04-01 |
| Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients (NCT00506311) | M.D. Anderson Cancer Center | 2003-02-01 |
| Study of Temzolomide and Gleevec in Advanced Melanoma (NCT00667953) | Abramson Cancer Center at Penn Medicine | 2003-01-01 |
| Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma (NCT00055562) | Celgene Corporation | 2003-01-01 |
| Melanoma Risk-Reduction Among Patients and Family Members (NCT00510302) | M.D. Anderson Cancer Center | 2002-11-18 |
| Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma (NCT00116597) | University Hospital, Basel, Switzerland | 2002-11-01 |
| Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma (NCT00050102) | Bristol-Myers Squibb | 2002-10-01 |
| Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma. (NCT00057616) | Celgene | 2002-10-01 |
| PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) (NCT00043368) | Pfizer | 2002-09-01 |
| Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma (NCT00040352) | National Cancer Institute (NCI) | 2002-07-01 |
| Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma (NCT00042497) | Anosys | 2002-07-01 |
| Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines (NCT00698100) | Memorial Sloan Kettering Cancer Center | 2002-06-01 |
| Fibrin Melanoma Axillary Node Study in Patients With Melanoma (NCT00504582) | M.D. Anderson Cancer Center | 2002-05-15 |
| Study of Karenitecin (BNP1350) to Treat Malignant Melanoma (NCT00062491) | BioNumerik Pharmaceuticals, Inc. | 2002-05-01 |
| EPO906 Therapy in Patients With Advanced Melanoma (NCT00035165) | Novartis Pharmaceuticals | 2002-03-01 |
| The Incidence of Breast and Other Cancers Among Female Flight Attendants (NCT00342407) | National Cancer Institute (NCI) | 2001-11-06 |
| Family Study of Melanoma in Italy (NCT00339222) | National Cancer Institute (NCI) | 2001-11-05 |
| Nonmyeloablative Allogeneic Transplant (NCT01272817) | Scripps Health | 2001-10-01 |
| Imatinib Mesylate in Treating Patients With Metastatic Melanoma (NCT00027586) | M.D. Anderson Cancer Center | 2001-09-01 |
| ADI-PEG in Patients With Metastatic Melanoma (NCT00029900) | FDA Office of Orphan Products Development | 2001-09-01 |
| Novel Adjuvants for Peptide-Based Melanoma Vaccines (NCT00028431) | University of Southern California | 2001-08-01 |
| Study of PI-88 in Patients With Advanced Melanoma (NCT00068172) | Cellxpert Biotechnology Corp. | 2001-07-01 |
| Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver (NCT00041808) | FeRx | 2001-07-01 |
| Phase II Trial of Allovectin-7® for Metastatic Melanoma (NCT00044356) | Vical | 2001-02-01 |
| Pain Relief - Tramadol Versus Ibuprofen (NCT00111046) | Royal Liverpool University Hospital | 2001-02-01 |
| Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer (NCT04180774) | N.N. Petrov National Medical Research Center of Oncology | 2001-01-31 |
| Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma (NCT00938223) | Craig L Slingluff, Jr | 2000-08-01 |
| Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer (NCT00588263) | Memorial Sloan Kettering Cancer Center | 2000-07-01 |
| Vaccine Therapy in Treating Patients With Metastatic Cancer (NCT00020267) | National Cancer Institute (NCI) | 2000-07-01 |
| Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma (NCT00386906) | M.D. Anderson Cancer Center | 2000-05-30 |
| Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma (NCT00912418) | Craig L Slingluff, Jr | 2000-05-01 |
| Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract (NCT00582647) | Memorial Sloan Kettering Cancer Center | 2000-03-01 |
| Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma (NCT00928902) | University of Virginia | 1999-11-01 |
| A Model for Genetic Susceptibility: Melanoma (NCT00591500) | Memorial Sloan Kettering Cancer Center | 1999-11-01 |
| Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma (NCT00001832) | National Cancer Institute (NCI) | 1999-08-01 |
| Evaluation for NCI Surgery Branch Clinical Research Protocols (NCT00001823) | National Cancer Institute (NCI) | 1999-07-11 |
| Microarray Analysis for Human Genetic Disease (NCT00001898) | National Human Genome Research Institute (NHGRI) | 1999-06-29 |
| Ultrasound Biomicroscopy - Apoptosis (NCT00188370) | University Health Network, Toronto | 1999-04-01 |
| Genetic Analysis of Familial Melanoma (NCT00339404) | National Human Genome Research Institute (NHGRI) | 1999-03-04 |
| Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma (NCT00406900) | Ludwig-Maximilians - University of Munich | 1999-01-01 |
| Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research (NCT05539677) | N.N. Petrov National Medical Research Center of Oncology | 1998-09-01 |
| SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002) (NCT03552549) | Merck Sharp & Dohme LLC | 1998-08-05 |
| Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence (NCT00001705) | National Cancer Institute (NCI) | 1998-07-01 |
| Melanoma: Genomic Profiles, Molecular Markers and Therapeutic Implications (NCT05119829) | Hellenic Cooperative Oncology Group | 1998-02-01 |
| Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase (NCT00001685) | National Cancer Institute (NCI) | 1997-11-01 |
| Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma (NCT00005617) | Jonsson Comprehensive Cancer Center | 1997-07-01 |
| Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity (NCT00001577) | National Cancer Institute (NCI) | 1997-06-01 |
| Differential Risks for Melanoma: p16 and DNA Repair (NCT00615095) | Memorial Sloan Kettering Cancer Center | 1997-02-01 |